CD19 dBTE

**CD19 dBTE** appears to refer generically to a **CD19-directed bispecific T-cell engager** rather than a single uniquely identifiable drug product. In this context, it most plausibly denotes an investigational dual-binding T-cell engager that binds **CD19** on malignant B cells and **CD3** on T cells to induce immune synapse formation, T-cell activation, and redirected cytotoxic killing of CD19-positive B-cell malignancies such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and diffuse large B-cell lymphoma. Because the queried name does not map unambiguously to one specific developer-backed molecule, the term is best treated as a non-specific descriptor for a CD19-targeting bispecific engager construct rather than a distinct commercial or clinical-stage drug.

Other names

CD19-directed bispecific T-cell engagerCD-19-directed bispecific T-cell engagerCD 19-directed bispecific T-cell engagerCD19xCD3 bispecific T-cell engagerCD-19xCD3 bispecific T-cell engagerCD 19xCD3 bispecific T-cell engager